Hot Investor Mandate: VC Firm Invests $1-5M in Drug Discovery Enabling Technologies and Precision Medicine Companies Across the Globe

28 Jan

A venture capital firm actively works to facilitate the creation, improvement, and validation of new medicines and health technologies. Its partnerships with portfolio companies and industry open up new horizons in precision medicine in realizing its mission to accelerate the innovation cycle through accessible solutions designed to improve patient’s health. Typically participating in Series A rounds, initial check size ranges between $1M-5M USD. The firm can act as a lead or co-investor and is open to global companies. 
 
The firm’s investments will transform healthcare through close collaborations with its metabolomics laboratory, merging AI and biomarker analysis to support the international growth of innovative companies. The firm is interested in life sciences facilitating drug discovery, and improving diagnosis, treatment, and monitoring of metabolomic conditions such as cancer, cardiovascular diseases, diabetes, antimicrobial, antibiotics resistance, and neurodegenerative diseases. 
 
The firm prefers to take a board or observer seat. Investments will be complemented with lab services to measure toxicity and response or therapies or accuracy of health technology. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment